I'm LongbridgeAI, I can summarize articles.JP Morgan maintained BeOne Medicines at Overweight and raised its price target to $460 from $445, a 3.4% increase.
The price target implies an upside of 68.3% from the Nov 19 close of $273.29.
Recent analyst actions on BeOne Medicines
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 13 | Morgan Stanley | Maintains | Overweight | $476 |
| Nov 6 | RBC Capital | Maintains | Outperform | $465 |
| Nov 6 | Truist Securities | Reiterates | Buy | $448 |
| Nov 6 | Barclays | Maintains | Overweight | $446 |
| Nov 6 | Citizens | Maintains | Market Outperform | $463 |
Across the five most recent analyst notes published on BeOne Medicines over the past 30 days, price targets range from $446 to $476.
Explore more price target data and ratings for BeOne Medicines on the , and track all previous and future analyst recommendations in the dedicated News Flow.
Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.
